Seminars in Diagnostic Pathology
Volume 25, Issue 4 , Pages 274-287 , November 2008

Molecular targets and biological modifiers in gastric cancer

  • Fátima Carneiro, MD, PhD

      Affiliations

    • Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
    • Medical Faculty of the University of Porto, Porto, Portugal
    • Department of Pathology, Hospital S. João, Porto, Portugal
    • Corresponding Author InformationAddress reprint requests and correspondence: Fátima Carneiro, MD, PhD, Rua Dr Roberto Frias s/n, 4200-465 Porto, Portugal
    • ,
  • Carla Oliveira, PhD

      Affiliations

    • Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
    • Medical Faculty of the University of Porto, Porto, Portugal
    • ,
  • Marina Leite, PhD

      Affiliations

    • Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
    • ,
  • Raquel Seruca, MD, PhD

      Affiliations

    • Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
    • Medical Faculty of the University of Porto, Porto, Portugal

References 

  1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. In:  Ferlay J,  Bray F,  Pisani P, et al. editor. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, Version 2.0. Lyon, France: IARC Press; 2004;
  3. Carneiro F. Classification of gastric carcinomas. Curr Diagn Pathol. 1997;4:51–59
  4. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma (An attempt at a histoclinical classification). Acta Pathol Microbiol Scand. 1965;64:31–49
  5. Henson DE, Dittus C, Younes M, et al. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765–770
  6. Carneiro F, Seixas M, Sobrinho–Simões M. New elements for an updated classification of the carcinomas of the stomach. Pathol Res Pract. 1995;191:571–584
  7. Ekstrom AM, Serafini M, Nyren O, et al. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. Int J Cancer. 2000;87:133–140
  8. Palli D, Galli M, Caporaso NE, et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev. 1994;3:15–18
  9. Carneiro F, Oliveira C, Suriano G, et al. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer (HDGC). J Clin Pathol. 2008;61:25–30
  10. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–405
  11. Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36:873–880
  12. Chun YS, Lindor NM, Smyrk TC, et al. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated?. Cancer. 2001;92:181–187
  13. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001;344:1904–1909
  14. Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203:681–687
  15. Charlton A, Blair V, Shaw D, et al. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut. 2004;53:814–820
  16. Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol. 2006;4:262–275
  17. Rogers WM, Dobo E, Norton JA, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol. 2008;32:799–809
  18. Lynch HT, Kaurah P, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer. 2008;112:2655–2663
  19. Shore EM, Nelson WJ. Biosynthesis of the cell adhesion molecule uvomorulin (E-cadherin) in Madin-Darby canine kidney epithelial cells. J Biol Chem. 1991;266:19672–19680
  20. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev. 2003;83:337–376
  21. Berx G, Becker KF, Höfler H, et al. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat. 1998;12:226–237
  22. Oliveira C, Seruca R, Carneiro F. Genetics, pathology and clinics of familial gastric cancer. Int J Surg Pathol. 2006;14:21–33
  23. Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet. 2000;26:16–17
  24. Oliveira C, de Bruin J, Nabais S, et al. Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene. 2004;23:2236–2240
  25. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820–823
  26. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. J Am Med Assoc. 2007;297:2360–2372
  27. Lynch HT, Grady W, Suriano G, et al. Gastric cancer: new genetic developments. J Surg Oncol. 2005;90:114–133
  28. Fitzgerald RC, Caldas C. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut. 2004;53:775–778
  29. Suriano G, Oliveira C, Ferreira P, et al. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet. 2003;12:575–582
  30. Suriano G, Seixas S, Rocha J, et al. A model to infer the pathogenic significance of CDH1 germline missense variants. J Mol Med. 2006;84:1023–1031
  31. Becker KF, Höfler H. Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas. J Natl Cancer Inst. 1995;87:1082–1084
  32. Machado JC, Oliveira C, Carvalho R, et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 2001;20:1525–1528
  33. Corso G, Roviello F, Paredes J, et al. Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. Eur J Surg Oncol. 2007;33:1061–1067
  34. Chang YF, Imam JS, Wilkinson MF. The nonsense-mediated decay RNA surveillance pathway. Annu Rev Biochem. 2007;76:51–74
  35. Holbrook JA, Neu–Yilik G, Hentze MW, et al. Nonsense-mediated decay approaches the clinic. Nat Genet. 2004;36:801–808
  36. Wilkinson MF. A new function for nonsense-mediated mRNAdecay factors. Trends Genet. 2005;21:143–148
  37. Karam R, Carvalho J, Bruno I, et al. The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers. Oncogene. 2008;Apr 21 [Epub ahead of print]
  38. Sasaki CY, Lin H, Morin PJ, et al. Truncation of the extracellular region abrogates cell contact but retains the growth-suppressive activity of E-cadherin. Cancer Res. 2000;60:7057–7065
  39. Yap AS, Kovacs EM. Direct cadherin-activated cell signaling: a view from the plasma membrane. J Cell Biol. 2003;160:11–16
  40. Crepaldi T, Pollack AL, Prat M, et al. Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells. J Cell Biol. 1994;125:313–320
  41. Hoschuetzky H, Aberle H, Kemler R. Beta-catenin mediates the interaction of the cadherin–catenin complex with epidermal growth factor receptor. J Cell Biol. 1994;127:1375–1380
  42. Qian X, Karpova T, Sheppard AM, et al. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 2004;23:1739–1748
  43. Mateus AR, Seruca R, Machado JC, et al. EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells. Human Mol Genet. 2007;16:1639–1647
  44. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2001;2:127–137
  45. den Hartigh JC, van Bergen en Henegouwen PM, Verkleij AJ, et al. The EGF receptor is an actin-binding protein. J Cell Biol. 1992;119:349–355
  46. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509–514
  47. Nobes CD, Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol. 1999;144:1235–1244
  48. Comoglio PM, Boccaccio C, Trusolino L. Interactions between growth factor receptors and adhesion molecules: breaking the rules. Curr Opin Cell Biol. 2003;15:565–571
  49. Ruoslahti E, Reed JC. Anchorage dependence, integrins, and apoptosis. Cell. 1994;77:477–478
  50. Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol. 1997;9:701–706
  51. Ihara A, Koizumi H, Hashizume R, et al. Expression of epithelial cadherin and a- and b-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology. 1996;23:1441–1447
  52. Hirata K, Ajiki T, Okazaki T, et al. Frequent occurrence of abnormal E-cadherin/β-catenin protein expression in advanced gallbladder cancers and its association with decreased apoptosis. Oncology. 2006;71:102–110
  53. Ferreira P, Oliveira MJ, Beraldi E, et al. Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. Exp Cell Res. 2005;310:99–104
  54. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61:203–212
  55. Klapper LN, Kirchbaum MH, Sela M, et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 2000;77:25–79
  56. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–354
  57. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139
  58. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500
  59. Moutinho C, Mateus AR, Milanezi F, et al. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer. 2008;8:10
  60. Akiyama T, Sudo C, Ogawara H, et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232:1644–1646
  61. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics. 1989;4:362–366
  62. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  63. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199:418–423
  64. McKenzie SJ, DeSombre KA, Bast BS, et al. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer. 1993;71:3942–3946
  65. Hirashima N, Takahashi W, Yoshii S, et al. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol. 2001;14:556–562
  66. Cohen JA, Weiner DB, More KF, et al. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene. 1989;4:81–88
  67. David L, Seruca R, Nesland JM, et al. c-erbB-2 expression in primary gastric carcinomas and their metastases. Mod Pathol. 1992;5:384–390
  68. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer. 1999;85:1894–1902
  69. Takehana T, Kunitomo K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 2002;98:833–837
  70. Varis A, Zaika A, Puolakkainen P, et al. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer. 2004;109:548–553
  71. Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51:1371–1379
  72. Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol. 2007;38:1386–1393
  73. Kimura M, Tsuda H, Morita D, et al. A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch. 2004;445:255–262
  74. Vulfovich M, Rocha–Lima C. Novel advances in pancreatic cancer treatment. Expert Rev Anticancer Ther. 2008;8:993–1002
  75. Slamon DJ, Leyland–Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  76. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  77. Piccart–Gebhart MJ, Procter M, Leyland–Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  78. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273–278
  79. Rebischung C, Barnoud R, Stefani L, et al. The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer. 2005;8:249–252
  80. Peltomaki P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet. 2001;10:735–740
  81. Liu B, Nicolaides NC, Markowitz S, et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet. 1995;9:48–55
  82. Peltomaki P, Lothe RA, Aaltonen LA, et al. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res. 1993;53:5853–5855
  83. Seruca R, Santos NR, David L, et al. Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile. Int J Cancer. 1995;64:32–36
  84. dos Santos NR, Seruca R, Constância M, et al. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology. 1996;110:38–44
  85. Chung YJ, Park SW, Song JM, et al. Evidence of genetic progression in human gastric carcinomas with microsatellite instability. Oncogene. 1997;15:1719–1726
  86. Hayden JD, Cawkwell L, Quirke P, et al. Prognostic significance of microsatellite instability in patients with gastric carcinoma. Eur J Cancer. 1997;33:2342–2346
  87. Oliveira C, Seruca R, Seixas M, et al. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different “target genes”: a study of the TGFbeta RII, IGFII R, and BAX genes. Am J Pathol. 1998;153:1211–1219
  88. Fleisher AS, Esteller M, Wang S, et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 1999;59:1090–1095
  89. Halling KC, Harper J, Moskaluk CA, et al. Origin of microsatellite instability in gastric cancer. Am J Pathol. 1999;155:205–211
  90. Kang GH, Shim YH, Ro JY, et al. Correlation of methylation of the hMLH1 promoter with lack of expression of hMLH1 in sporadic gastric carcinomas with replication error. Lab Invest. 1999;79:903–909
  91. Leung SY, Yuen ST, Chung LP, et al. hMLH1 promoter hypermethylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res. 1999;59:159–164
  92. Yamamoto H, Perez–Piteira J, Yoshida T, et al. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology. 1999;116:1348–1357
  93. Pinto M, Oliveira C, Machado JC, et al. MSI-L gastric carcinomas share the hMLH1 methylation status of MSI-H carcinomas but not their clinicopathological profile. Lab Invest. 2000;80:1915–1923
  94. Aarnio M, Salovaara R, Aaltonen LA, et al. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer. 1997;74:551–555
  95. Pinto M, Wu Y, Mensink RG, et al. Somatic mutations in mismatch repair genes in sporadic gastric carcinomas are not a cause but a consequence of the mutator phenotype. Cancer Genet Cytogenet. 2008;18:110–114
  96. Suzuki H, Itoh F, Toyota M, et al. Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int J Cancer. 1999;83:309–313
  97. Toyota M, Ahuja N, Suzuki H, et al. Aberrant methylation in gastric cancer associated with CpG island methylator phenotype. Cancer Res. 1999;59:5438–5442
  98. Latham KE. X chromosome imprinting and inactivation in the early mammalian embryo. Trends Genet. 1996;12:134–138
  99. Issa JP, Ottaviano YL, Celano P, et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7:536–540
  100. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–3229
  101. Nguyen C, Liang G, Nguyen TT, et al. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst. 2001;93:1465–1472
  102. Kikuchi T, Itoh F, Toyota M, et al. Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer. Int J Cancer. 2002;97:272–277
  103. Kang GH, Shim YH, Jung HY, et al. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 2001;61:2847–2851
  104. Fleisher AS, Esteller M, Tamura G, et al. Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene. 2001;20:329–335
  105. Carvalho B, Pinto M, Cirnes L, et al. Concurrent hypermethylation of gene promoters is associated with a MSI-H phenotype and diploidy in gastric carcinomas. Eur J Cancer. 2003;39:1222–1227
  106. Song SH, Jong HS, Choi HH, et al. Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 50 CpG island in human gastric carcinoma cells. Cancer Res. 2001;61:4628–4635
  107. Nakagawa H, Nuovo GJ, Zervos EE, et al. Age-related hypermethylation of the 50 region of HMLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res. 2001;61:6991–6995
  108. Tamura G, Yin J, Wang S, et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst. 2000;92:569–573
  109. Lee TL, Leung WK, Chan MW, et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res. 2002;8:1761–1766
  110. Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793–797
  111. Park TJ, Han SU, Cho YK, et al. Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer. 2001;92:2760–2768
  112. Mitra G, Pauly GT, Kumar R, et al. Molecular analysis of O6- substituted guanine-induced mutagenesis of ras oncogenes. Proc Natl Acad Sci USA. 1989;86:8650–8654
  113. Beghelli S, de Manzoni G, Barbi S, et al. Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery. 2006;139:347–356
  114. Duval A, Reperant M, Compoint A, et al. Target gene mutation profile differs between gastrointestinal and endometrial tumors with mismatch repair deficiency. Cancer Res. 2002;62:1609–1612
  115. Davalos V, Dopeso H, Velho S, et al. High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene. 2007;26:308–311
  116. Amendt C, Schirmacher P, Weber H, et al. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene. 1998;17:25–34
  117. Attisano L, Wrana JL, Lopez–Casillas F, et al. TGF-beta receptors and actions. Biochim Biophys Acta. 1994;1222:71–80
  118. Derynck R. TGF-beta-receptor-mediated signaling. Trends Biochem Sci. 1994;19:548–553
  119. Wrana JL, Attisano L, Carcamo J, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 1992;71:1003–1014
  120. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signaling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390:465–471
  121. Carcamo J, Zentella A, Massague J. Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol Cell Biol. 1995;15:1573–1581
  122. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336–1338
  123. Souza RF, Appel R, Yin J, et al. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nature Genet. 1996;14:255–257
  124. Dahms NM, Lobel P, Kornfeld S. Mannose 6-phosphate receptors and lysosomal enzyme targeting. J Biol Chem. 1989;264:12115–12118
  125. Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA. 1991;88:580–584
  126. Kornfeld S. Structure and function of the mannose 6-phosphate/insulin-like growth factor type II receptors. Annu Rev Biochem. 1992;61:307–330
  127. Falchetti M, Saieva C, Lupi R, et al. Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol. 2008;39:925–932
  128. Minniti CP, Kohn EC, Grubb JH, et al. The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells. J Biol Chem. 1992;267:9000–9004
  129. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954
  130. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934
  131. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002;62:6451–6455
  132. Brennetot C, Duval A, Hamelin R, et al. Frequent Ki-ras mutations in gastric tumors of the MSI phenotype. Gastroenterology. 2003;125:1282
  133. Oliveira C, Pinto M, Duval A, et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene. 2003;22:9192–9196
  134. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005;24:1477–1480
  135. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005;41:1649–1654
  136. Li V, Wong C, Chan T, et al. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. 2005;5:29
  137. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554
  138. Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17:615–675
  139. Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta. 1998;1436:127–150
  140. Byun DS, Cho K, Ryu BK, et al. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int J Cancer. 2003;104:318–327
  141. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501
  142. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3:1221–1224
  143. Osaki M, Kase S, Adachi K, et al. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line (MKN-45). J Cancer Res Clin Oncol. 2004;130:8–14
  144. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004;9:667–676
  145. Kim DW, Huamani J, Fu A, et al. Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. Int J Radiat Oncol Biol Phys. 2006;64:38–46
  146. Ng SSW, Tsao M-S, Chow S, et al. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000;60:5451–5455
  147. Sarkaria JN, Tibbetts RS, Busby EC, et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 1998;58:4375–4382
  148. Samuels Y, Diaz LAJ, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7:561–573
  149. Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005;65:4562–4567
  150. Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005;65:10992–11000
  151. Zhao JJ, Liu Z, Wang L, et al. The oncogenic properties of mutant p110{alpha} and p110{beta} phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA. 2005;102:18443–18448
  152. Kang S, Bader AG, Zhao L, et al. Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle. 2005;4:578–581
  153. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004;91:1420–1424

PII: S0740-2570(08)00058-0

doi: 10.1053/j.semdp.2008.07.004

Seminars in Diagnostic Pathology
Volume 25, Issue 4 , Pages 274-287 , November 2008

Article Tools

* Image Usage & Resolution